Misbranding refers to issues related to which of the following?

• A. Drug safety data sheets
• B. Labeling, label, packaging, or package insert
• C. Manufacturing temperature controls
• D. Expiration dating accuracy

Answer: (B)

Misbranding centers on what the drug’s label and packaging communicate to users and whether that information is true, complete, and not misleading. The labeling must convey directions for use, dosage, warnings, indications, and other essential details, while packaging and the package insert provide the official information that accompanies the product. When this information is false, misleading, or incomplete, the product is considered misbranded. The option that describes labeling, packaging, or the package insert matches this domain exactly, making it the best answer. The other options relate to safety handling (drug safety data sheets) or quality/processing aspects (manufacturing conditions, dating) rather than the communication on the label and packaging itself.